Entrada Therapeutics — Third Quarter 2026 Earnings Summary

Entrada Therapeutics reported a net loss of $39.7 million for the third quarter of 2026, with cash, cash equivalents, and marketable securities totaling $193 million as of September 30, 2026. The company announced that Cohort 1 participants in the ELEVATE-44-201 study have completed open-label dosing, with data expected by year-end 2026, while ELEVATE-45-201 Cohort 1 data demonstrated favorable safety and tolerability at a 5 mg/kg dose. Clinical enrollment is complete for ELEVATE-45-201 Cohort 2, with data anticipated in the first half of 2027, and the company expects its cash runway to extend into the fourth quarter of 2027. Additionally, the U.S. FDA granted orphan drug designation for ENTR-601-45, and the company plans to nominate a second clinical candidate for an ocular disease by the end of 2026.